Phacogenic glaucoma

Summary

Phacogenic glaucoma (MONDO:0001554) is a disease. A subtype of glaucoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	phacogenic glaucoma
Mondo ID	MONDO:0001554
DOID	DOID:12571
SNOMED CT	392300000
UMLS	C0271142
MedGen	543189
Is cancer (heuristic)	no

Also known as: phacomorphic glaucoma

Disease family

This is a subtype of glaucoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › glaucoma › phacogenic glaucoma

Related subtypes (10): glaucomatous atrophy of optic disk, hypersecretion glaucoma, aqueous misdirection, traumatic glaucoma, angle-closure glaucoma, borderline glaucoma, steroid-induced glaucoma, open-angle glaucoma, hereditary glaucoma, secondary early-onset glaucoma

Subtypes (2): phacolytic glaucoma, exfoliation syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.